Pharmacyclics (PCYC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (520)	9/13/1999 6:52:00 PM
From: scaram(o)uche	Read Replies (1) of 717

Monday September 13, 5:01 pm Eastern Time Company Press Release SOURCE: CIBA Vision CIBA Vision and QLT Announce Treatment-Investigational New Drug Program For Visudyne Therapy for Wet AMD in North America Clinical Trial Offers Additional, Controlled Access to Therapy Prior To Regulatory approval ATLANTA and VANCOUVER, British Columbia, Sept. 13 /PRNewswire/ -- CIBA Vision, the eye care unit of Novartis AG, and QLT PhotoTherapeutics (Nasdaq: QLTI - news) announced today the initiation of a Treatment-Investigational New Drug (T-IND) clinical program for Visudyne therapy for the treatment of the wet form of age-related macular degeneration (AMD). The program, for which enrollment will begin September 15, will provide Visudyne therapy within a controlled, clinical setting, prior to regulatory approval, to a certain number of patients who meet specific eligibility criteria. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next